A routine blood count could contain a surprisingly broad warning signal for metabolic syndrome, according to a large analysis of U.S. health data. Researchers examining 15,846 adults who participated in the National Health and Nutrition Examination Survey, or NHANES, from 2013 through 2020 found that people with higher pan-immune-inflammation values were more likely to have metabolic syndrome. The association persisted after the investigators adjusted for a wide range of demographic, lifestyle and clinical factors, suggesting that the relationship was not explained simply by age, sex or body weight. Metabolic syndrome is not a single disease but a cluster of abnormalities—including abdominal obesity, elevated blood pressure, high blood sugar, high triglycerides and reduced levels of protective HDL cholesterol—that together raise the risk of cardiovascular disease, stroke and type 2 diabetes. Of the participants included in the analysis, 3,845 met the study’s definition of metabolic syndrome.

The biomarker at the center of the study, known as the pan-immune-inflammation value, or PIV, is designed to combine information from several types of blood cells into one numerical estimate of systemic inflammatory activity. It is generally calculated using platelet, neutrophil, monocyte and lymphocyte counts: platelet count multiplied by neutrophil count and monocyte count, divided by lymphocyte count. Each component reflects a different aspect of the body’s immune and inflammatory state. Neutrophils and monocytes are innate immune cells that can rise during inflammation, while lymphocytes represent an important arm of adaptive immunity. Platelets participate in clotting but also interact with immune cells and blood-vessel walls. By integrating these measurements, PIV may capture a more complex biological pattern than any one cell count or a simpler ratio such as the neutrophil-to-lymphocyte ratio.

The new analysis does not show that inflammation causes metabolic syndrome, nor does it establish that PIV can diagnose the condition. Instead, it identifies a statistical association in a nationally representative, cross-sectional dataset. The researchers divided participants into four groups, or quartiles, according to their PIV values and compared the prevalence of metabolic syndrome across those groups. They then used weighted statistical models designed to account for the complex sampling structure of NHANES, which combines interviews, physical examinations and laboratory measurements to represent the civilian U.S. population. The investigators applied multivariable logistic regression, sensitivity analyses, subgroup comparisons and restricted cubic spline modeling to explore whether the relationship remained after accounting for potential confounding factors and whether it followed a straight-line pattern.

Across four increasingly adjusted statistical models, higher PIV was consistently linked to greater odds of metabolic syndrome. In the least adjusted model, each increase in the analyzed PIV measure was associated with an odds ratio of 1.19, with a 95 percent confidence interval from 1.13 to 1.26. After additional variables were introduced, the association remained statistically significant: the odds ratios were 1.17, 1.19 and finally 1.12 in the most fully adjusted model. The last estimate had a 95 percent confidence interval of 1.04 to 1.19 and a P value of 0.002. An odds ratio above one indicates higher odds of the outcome, although it should not be interpreted as a direct increase in an individual’s absolute risk. The confidence intervals also indicate uncertainty around each estimate; because they did not cross one, the researchers considered the associations statistically significant.

The pattern was not perfectly linear. Restricted cubic spline analysis, a flexible statistical technique that allows the data to curve rather than forcing them into a straight line, detected a nonlinear relationship between PIV and metabolic syndrome, with a P value of 0.044 for nonlinearity. This suggests that the change in metabolic-syndrome odds may not be identical at every point on the PIV scale. In biological terms, inflammation could have different implications at relatively low, intermediate or very high levels, or the association could reflect interactions with obesity, insulin resistance, liver dysfunction, kidney disease or medication use. The analysis found a positive relationship across the PIV range, but the detailed shape of that relationship would need to be tested in prospective studies before it could guide clinical thresholds.

To examine whether the result was being driven by specific types of participants, the researchers performed stratified analyses across subgroups. The positive association between PIV and metabolic syndrome remained broadly consistent, rather than disappearing in one particular demographic or clinical category. The investigators also repeated the analysis after excluding people taking fibrates or omega-3 products, which can affect blood lipids, as well as medications used to lower blood glucose or blood pressure. In that restricted sample, the association became stronger, with an odds ratio of 1.73 and a 95 percent confidence interval from 1.26 to 2.38. This finding may indicate that treatment-related changes in metabolic measurements or blood-cell profiles had partly obscured the relationship in the full dataset, although it could also reflect differences between people who do and do not receive those medications.

The researchers tested additional definitions and methods to assess the robustness of their findings. PIV remained significantly and positively associated with metabolic syndrome when the condition was defined using the Harmonized criteria, an internationally developed approach that brings together several commonly used diagnostic thresholds. Missing data were also addressed using random forest imputation, a machine-learning method that estimates absent values from patterns in the observed data. With that approach, the association remained stable in the first three models but weakened in the most fully adjusted model. Such attenuation is important: it shows that the strength of the association can depend on how missing information and potential confounders are handled, even when the overall signal remains suggestive.

Metabolic syndrome has long been linked to chronic, low-grade inflammation. Excess visceral fat—the metabolically active fat stored around internal organs—can release inflammatory signaling molecules and attract immune cells. These signals may interfere with insulin action, promote abnormal lipid metabolism and impair the function of the vascular endothelium, the cell layer lining blood vessels. Insulin resistance can lead the pancreas to produce more insulin to maintain normal blood glucose, while the liver may continue releasing glucose and producing triglyceride-rich particles. At the same time, inflammation and oxidative stress can alter platelet activity and leukocyte behavior. A composite measure such as PIV could therefore reflect several biological processes that overlap with the development or expression of metabolic syndrome, although it cannot reveal which process comes first.

The potential appeal of PIV is practical as much as biological. Platelet and white-cell counts are routinely included in complete blood counts, making the components relatively inexpensive and widely available compared with specialized inflammatory assays. If future research confirms that PIV adds meaningful information beyond waist circumference, blood pressure, glucose and lipid measurements, it could become a supplementary risk marker for identifying people who warrant closer metabolic evaluation. But the current study is not sufficient to support that use. NHANES provides a powerful population snapshot, yet its cross-sectional design measures exposure and outcome at roughly the same time. The data cannot establish whether elevated PIV precedes metabolic syndrome, results from it, or is influenced by an unmeasured factor such as infection, smoking, diet, medication, chronic disease or socioeconomic conditions.

The authors, led by Qian Dai and colleagues at Shanghai Fifth People’s Hospital affiliated with Fudan University and Fudan University’s Center for Community-Based Health Research, conclude that higher PIV is positively associated with the presence of metabolic syndrome among U.S. adults. They emphasize that prospective cohort studies in diverse populations are needed to determine whether the biomarker can predict future metabolic syndrome and whether it offers advantages over established measures of inflammation and insulin resistance. Clinical trials would also be needed to learn whether changing PIV through lifestyle or medical treatment changes metabolic outcomes, rather than merely accompanying them. For now, the study adds PIV to a growing list of inflammation-related indicators connected with cardiometabolic health. Its most important message is not that a single blood index can replace standard screening, but that the immune system, blood cells and metabolism may be more tightly intertwined than conventional checkups reveal.

Chronic inflammation is known to play a significant role in the progression of many diseases, particularly those associated with metabolic syndromes. The PIV is a novel marker, integrating multiple facets of immune response and inflammation into a singular measure. This study articulates how elevated levels of this marker can correlate with worsening stages of diabetic retinopathy among individuals diagnosed with type 2 diabetes. Such findings could revolutionize how practitioners approach early detection and management of diabetic retinopathy.

Existing literature has long recognized that diabetes is accompanied by a state of low-grade systemic inflammation. However, the specifics of how this inflammation translates into ocular complications have remained less defined. The research team embarked on this study with a hypothesis that high PIV levels would equate to an increased severity of diabetic retinopathy. The hope was to furnish clinicians with a tool to assess risk more effectively and perhaps intervene before irreversible damage occurred.

The study’s methodology involved the recruitment of a diverse cohort of patients diagnosed with type 2 diabetes from various outpatient clinics. Each participant underwent thorough clinical evaluations, including retinal imaging to determine the stage of diabetic retinopathy. Additionally, blood samples were taken to measure the pan-immune inflammation value alongside other traditional markers of inflammation, such as C-reactive protein (CRP) and interleukins.

Intriguingly, the results of the study were compelling. A clear gradient emerged, showing that as the PIV increased, the stages of diabetic retinopathy advanced accordingly. For instance, patients with mild non-proliferative diabetic retinopathy exhibited lower PIV levels compared to those with moderate or severe stages. This finding reinforces the concept that systemic inflammation does not merely coexist with diabetes but actively contributes to its complications.

Furthermore, the researchers did not just stop at identifying this relationship; they delved deeper into the underlying mechanisms of how inflammation mediates retinal health. Previous studies have established that the retina is not only affected by local factors but also by systemic conditions. The vascular changes induced by inflammatory mediators can result in the leakage of fluid and the formation of microaneurysms, both hallmark signs of diabetic retinopathy.

The inclusion of PIV as a routine assessment could pivotally change the landscape of diabetic care. By utilizing a marker that reflects the immune system’s ongoing battle with inflammation, healthcare providers might be able to classify patients according to risk and customize management plans accordingly. This could entail earlier referrals for ophthalmological evaluation, aggressive glycemic control, and lifestyle interventions aimed at reducing inflammation.

However, transitioning from findings to clinical practice necessitates further research. The authors advocate for longitudinal studies that encompass diverse populations and varying degrees of diabetes management. Long-term studies could illuminate the predictive capabilities of PIV and solidify its place in the clinical workup of diabetic patients.

Moreover, the advent of personalized medicine means that markers such as PIV could help in tailoring therapeutic options for individual patients. If validated, treatments targeting inflammation could emerge as a pivotal focal point in mitigating the progression of diabetic retinopathy, sparing patients from the futility of vision loss.

As with all scientific inquiries, the study by Bulut and Keser is but a stepping stone in unraveling the complexities surrounding diabetic complications. The juxtaposition of immune response, systemic inflammation, and vascular health encapsulates the multi-faceted nature of diabetes management. The findings implore the medical community to look beyond glucose levels and consider inflammation as a pivotal player in the diabetic trajectory.

Ultimately, the relationship between pan-immune inflammation value and stages of diabetic retinopathy forms a critical area of focus for future investigations. It offers hope for patients and clinicians alike: a new frontier in understanding, preventing, and potentially reversing one of the most challenging complications of diabetes. As the body of evidence grows, the implications of such research could catalyze a paradigm shift in how diabetic retinopathy is approached globally, encouraging a more integrated model of care that encompasses systemic health.

The urgency of addressing diabetic retinopathy, given its prevalence and the devastating impact of exudative retinal disease, cannot be understated. Each discovery propels researchers closer to strategies that can reduce incidences, aid early detection, and arms healthcare providers with the knowledge necessary to thwart the march toward blindness in diabetic populations. The journey towards a comprehensive understanding of the relationship between inflammation and retinopathy is not just academic; it is profoundly human, affecting millions around the world.

As diabetes continues to rise to epidemic proportions, so too must our commitment to discovering innovative solutions. The implications of Bulut and Keser’s study may well have far-reaching effects, propelling new dialogues in ophthalmology and endocrinology and ultimately altering the outcomes for countless individuals grappling with the specter of diabetes.

Subject of Research: The relationship between pan-immune inflammation value and different stages of diabetic retinopathy in patients with type 2 diabetes mellitus.

Article Title: The relationship between pan-immune inflammation value and different stages of diabetic retinopathy in patients with type 2 diabetes mellitus: a prospective cross-sectional study.

Article References:

Bulu, A., Keser, S. The relationship between pan-immune inflammation value and different stages of diabetic retinopathy in patients with type 2 diabetes mellitus: a prospective cross-sectional study.
BMC Endocr Disord 25, 184 (2025). https://doi.org/10.1186/s12902-025-02007-x

Image Credits: AI Generated

DOI: 10.1186/s12902-025-02007-x

Keywords: diabetic retinopathy, type 2 diabetes, pan-immune inflammation value, inflammation, systemic health.

Wilms’ tumor accounts for a significant proportion of childhood kidney cancers, and despite advances in multimodal therapies, prognostic accuracy remains elusive. Traditional staging and histopathological assessments have provided a foundation, yet they fall short in capturing the nuanced systemic inflammatory responses that seem intricately linked to tumor biology and chemotherapy tolerance. Against this backdrop, the study published in BMC Cancer introduces PIV — an integrative biomarker derived from routine blood parameters — as an innovative prognostic tool with clinical ramifications that extend from survival prediction to the anticipation of chemotherapy-related adverse events (CRAEs).

The research employed a robust methodological framework, enrolling WT patients through a comprehensive retrospective analysis at a single institution. Crucially, the team measured various inflammatory indices before initiating any treatment, focusing on immune cell ratios that reflect the host’s systemic inflammatory status. By leveraging Kaplan-Meier survival estimates alongside Cox proportional hazards models, the investigators discerned definitive correlations between elevated PIV values and decreased event-free survival (EFS), overall survival (OS), as well as a heightened susceptibility to chemotherapy-induced complications.

Among the panel of inflammatory biomarkers scrutinized, PIV emerged as a singularly potent predictor. This index encapsulates neutrophil, monocyte, platelet counts, and lymphocyte levels into a composite metric that reflects the intricate balance between pro-tumor inflammatory processes and anti-tumor immune responses. Strikingly, patients exhibiting PIV values beyond a calculated threshold of 246.4 demonstrated not only a significant fourfold risk increase for unfavorable events but also a more than fivefold risk escalation for mortality, underscoring its strong prognostic relevance.

Diving deeper into statistical analyses, the study discerned that classical factors such as tumor stage remained critical, with stage IV disease conferring an augmented hazard ratio for mortality. However, when integrated with PIV, the predictive accuracy of models improved markedly. This synergistic interplay suggests that PIV is not merely a supplementary marker but could function as a central axis in prognostication models, enabling clinicians to stratify patients with unprecedented precision.

Furthermore, the investigation revealed the neutrophil-to-lymphocyte ratio (NLR), an established inflammatory marker, as an independent prognostic factor with an inverse association to event-free survival. This finding intriguingly reflects the complex immunological landscape in WT patients, where the balance between innate and adaptive immunity could tilt survival trajectories in either direction. The subtle yet significant modulation of NLR reinforces the necessity to consider multiple facets of the immune response rather than isolated parameters.

Beyond survival metrics, a particularly novel aspect of this study is the association of high PIV levels with an elevated incidence of chemotherapy-related adverse events. Chemotoxicity remains a formidable barrier in pediatric oncology, often necessitating dose reductions or treatment interruptions that compromise efficacy. Logistic regression analyses illustrated that patients with pronounced inflammatory status, as quantified by PIV, bore more than double the odds of experiencing severe CRAEs. This insight opens avenues for preemptive strategies tailored to patient-specific inflammatory profiles, potentially mitigating harm and improving quality of life during treatment.

The biological underpinnings of why systemic inflammation magnifies both tumor aggressiveness and chemotherapy intolerance are multifaceted. Chronic inflammation can facilitate tumor progression by fostering an immunosuppressive microenvironment, promoting angiogenesis, and inducing genetic instability. Concurrently, an overactive inflammatory milieu might exacerbate normal tissue toxicity under chemotherapeutic assault, amplifying adverse effects. Hence, PIV functions as a proxy for these deleterious inflammatory states, providing a window into both tumor biology and host susceptibility.

From a translational perspective, incorporating PIV into routine clinical workflows is feasible and cost-effective, given that it relies on parameters routinely measured in complete blood counts. Unlike molecular or genetic assays that demand high resources, PIV offers immediate accessibility, enabling oncologists to make informed decisions swiftly. Its integration could lead to personalized treatment protocols whereby patients with high PIV might receive intensified monitoring, adjunctive anti-inflammatory treatments, or modified chemotherapy dosing schedules.

The implications of this research are particularly profound in resource-limited settings, where advanced diagnostic technologies are scarce. By harnessing the prognostic power of PIV, healthcare providers can optimize care pathways, identifying high-risk patients early and allocating resources more judiciously. Moreover, PIV could serve as a critical endpoint in clinical trials, assessing the efficacy of novel therapeutics or anti-inflammatory interventions aimed at modulating the tumor-immune axis.

While the study offers compelling evidence for PIV’s utility, it also underscores the need for validation in larger, multi-institutional cohorts and prospective trials. Diverse patient populations with varying demographic and genetic backgrounds must be examined to consolidate these findings and explore potential confounders. Additionally, mechanistic studies delving into the cellular and molecular bases of PIV-related prognostic effects could further illuminate targeted therapeutic strategies.

The exploration of immune-inflammatory biomarkers in Wilms’ tumor heralds a paradigm shift towards integrative oncology, placing host-tumor interactions at the forefront of personalized medicine. As precision oncology evolves, markers like PIV exemplify the fusion of immunology and oncology, translating bench insights into bedside tools that enhance survival and reduce treatment morbidity.

In summary, the identification of the pan-immune-inflammation value as a robust predictor of prognosis and chemotherapy-related adverse events represents a significant leap forward in Wilms’ tumor management. This biomarker’s predictive capabilities extend beyond conventional staging, offering a holistic assessment of tumor behavior and patient resilience. As the pediatric oncology community strives for therapeutic precision and improved outcomes, integrating PIV into clinical practice promises to refine risk stratification and individualize treatment strategies, ultimately advancing the battle against this challenging malignancy.

Subject of Research: Prognostic biomarkers and chemotherapy-related adverse events in Wilms’ tumor patients.

Article Title: The pan-immune-inflammation value predicts prognosis and chemotherapy-related adverse events in Wilms’ tumor patients.

Article References:
Cui, K., Lin, J., Hong, P. et al. The pan-immune-inflammation value predicts prognosis and chemotherapy-related adverse events in Wilms’ tumor patients. BMC Cancer 25, 979 (2025). https://doi.org/10.1186/s12885-025-14391-7

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14391-7